Tarek M. Meniawy

Tarek M. Meniawy

Hospital Avenue
Nedlands, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Prognostic Value of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lactate Dehydrogenase Level in Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Prognostic Value of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lactate Dehydrogenase Level in Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Journal: Cancer investigation

Published: November 13, 2025

Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study.

Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study.

Journal: Cancer reports (Hoboken, N.J.)

Published: May 20, 2025

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.

Journal: Cancer chemotherapy and pharmacology

Published: March 07, 2025

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 26, 2024

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.

Journal: Gynecologic oncology

Published: June 28, 2024

Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series.

Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series.

Journal: Cancer reports (Hoboken, N.J.)

Published: March 13, 2024

Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.

Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.

Journal: Future oncology (London, England)

Published: February 23, 2024

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Journal: Nature medicine

Published: January 04, 2024

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.

Journal: NPJ precision oncology

Published: December 06, 2023

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

Journal: Nature medicine

Published: November 04, 2023

Showing 1-12 of 70

Last Updated: 09/26/2026